Literature DB >> 17853455

A boy with severe craniodiaphyseal dysplasia and apparently normal mother.

Tadeusz Bieganski1, Dobromila Baranska, Irmina Miastkowska, Artur Kobielski, Magdalena Gorska-Chrzastek, Kazimierz Kozlowski.   

Abstract

We describe a boy and his mother affected with craniodiaphyseal dysplasia (CDD). The boy had a very severe form of the disease with extensive osteosclerosis already at birth. Facial diplegia, bilateral hearing loss and optic nerve atrophy were early, severe complications of the disease. At age 7 years progressive genu valgum and unusual epimetaphyseal radiographic appearances suggested hyperparathyroidism. This was confirmed by biochemical tests. Because of some facial similarity between the asymptomatic mother and the propositus, a limited skeletal survey of the mother was performed. It demonstrated cranial osteosclerosis and hyperostosis. It is possible that the mother has somatic mosaicism for a mutation of the genes causing CDD. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17853455     DOI: 10.1002/ajmg.a.31938

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  3 in total

Review 1.  Human Genetics of Sclerosing Bone Disorders.

Authors:  Raphaël De Ridder; Eveline Boudin; Geert Mortier; Wim Van Hul
Journal:  Curr Osteoporos Rep       Date:  2018-06       Impact factor: 5.096

2.  Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia.

Authors:  Su Jin Kim; Tadeusz Bieganski; Young Bae Sohn; Kazimierz Kozlowski; Mikhail Semënov; Nobuhiko Okamoto; Chi Hwa Kim; Ah-Ra Ko; Geung Hwan Ahn; Yoon-La Choi; Sung Won Park; Chang-Seok Ki; Ok-Hwa Kim; Gen Nishimura; Sheila Unger; Andrea Superti-Furga; Dong-Kyu Jin
Journal:  Hum Genet       Date:  2011-01-09       Impact factor: 4.132

Review 3.  WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders.

Authors:  Yentl Huybrechts; Geert Mortier; Eveline Boudin; Wim Van Hul
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-09       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.